Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
Westhovens R, Houssiau F, Joly J, Everitt DE, Zhu Y, Sisco D, Van Hartingsveldt B, Mascelli MA, Graham MA, Durez P, Bouman-Thio E. Westhovens R, et al. Among authors: durez p. J Rheumatol. 2006 May;33(5):847-53. Epub 2006 Apr 1. J Rheumatol. 2006. PMID: 16583466 Clinical Trial.
Listeria infections associated with infliximab: case reports.
Kesteman T, Yombi JC, Gigi J, Durez P. Kesteman T, et al. Among authors: durez p. Clin Rheumatol. 2007 Dec;26(12):2173-2175. doi: 10.1007/s10067-007-0660-8. Epub 2007 Jun 20. Clin Rheumatol. 2007. PMID: 17579802
Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P. Durez P, et al. Arthritis Rheum. 2007 Dec;56(12):3919-27. doi: 10.1002/art.23055. Arthritis Rheum. 2007. PMID: 18050189 Free article. Clinical Trial.
The anti-CD20 antibody rituximab reduces the Th17 cell response.
van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, Gutierrez-Roelens I, Durez P, Netea MG, van der Meer JW, van den Berg WB, Joosten LA. van de Veerdonk FL, et al. Among authors: durez p. Arthritis Rheum. 2011 Jun;63(6):1507-16. doi: 10.1002/art.30314. Arthritis Rheum. 2011. PMID: 21400475 Free article. Clinical Trial.
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L, Arora V, Kavanaugh A. Smolen JS, et al. Among authors: durez p. Lancet. 2014 Jan 25;383(9914):321-32. doi: 10.1016/S0140-6736(13)61751-1. Epub 2013 Oct 26. Lancet. 2014. PMID: 24168956 Clinical Trial.
One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Ligozio G, Mpofu S. Genovese MC, et al. Among authors: durez p. J Rheumatol. 2014 Mar;41(3):414-21. doi: 10.3899/jrheum.130637. Epub 2014 Jan 15. J Rheumatol. 2014. PMID: 24429175 Clinical Trial.
171 results